The researchers also developed a mouse model of the mutation using CRISPR/Cas9 genome engineering to examine its effects.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
Evotec may use the technology for its drug-development and R&D activities, including in the development of research tools and in target identification.
Two teams independently characterized Cpf1's on-target efficiency and off-target specificity, publishing their results last month.
The partnership will place the Graham Cancer Center's Gene Editing Institute under the purview of the Wistar Institute's Molecular Screening Facility.
In Science this week: new chromatin imaging approach, and more.
University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.
Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.
Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.